Retatrutide 10 mg

1. The “Triple Agonist” Synergy Model Retatrutide is the primary subject of research regarding multi-receptor synergy. While previous generation peptides targeted one (GLP-1) or two (GLP-1/GIP) receptors, Retatrutide allows researchers to observe the cumulative effects of adding Glucagon Receptor (GCGR) activation.

• GLP-1R & GIPR: Studied for their role in delaying gastric emptying and modulating satiety signaling in the central nervous system.
• GCGR: Studied for its role in increasing energy expenditure and thermogenesis. This “Tri-Agonist” model is used to compare efficacy rates against mono- and dual-agonists in metabolic syndrome studies.

2. Glucagon-Mediated Thermogenesis & Lipid Oxidation Unlike Tirzepatide (a dual agonist), Retatrutide activates the Glucagon receptor. Research focuses on how this specific pathway stimulates hepatic lipid metabolism. Laboratory models observe the breakdown of stored glycogen and triglycerides (lipolysis) and the subsequent increase in Basal Metabolic Rate (BMR). This mechanism is critical for understanding how energy expenditure can be upregulated even during sleep cycles in murine models.
3. Hepatic Function & FGF21 Signaling Research indicates that Retatrutide’s action on the liver may be mediated through Fibroblast Growth Factor 21 (FGF21). Studies utilize this peptide to observe the downstream effects of FGF21 on adipocytes (fat cells), specifically the regulation of sugar intake preferences and mitochondrial activity. Models of Non-Alcoholic Fatty Liver Disease (NAFLD) utilize Retatrutide to measure reductions in liver fat content and improvements in lipid excretion.
4. Glycemic Control & Insulin Sensitivity In models of Type 2 Diabetes (db/db mice), Retatrutide is investigated for its profound impact on glucose homeostasis. Research monitors the reduction of Hemoglobin A1c (HbA1c) and the improvement of insulin sensitivity. The peptide serves as a tool for studying the preservation of beta-cell function and the modulation of insulinotropic pathways under hyperglycemic stress.
5. Cardiovascular Hemodynamics (Primate Models) Preclinical studies in cynomolgus monkeys have been conducted to assess the cardiovascular safety profile of triple agonists. Research monitors hemodynamic parameters, observing a dose-dependent increase in heart rate accompanied by a decrease in blood pressure. These studies are essential for understanding the long-term impact of incretin mimetics on endothelial function and ventricular activity.

Important Notices:

• Research Use Only: This product is sold strictly for scientific research and development purposes.
• Handling: The product is provided as a lyophilized powder. Reconstitution requires bacteriostatic water and sterile laboratory equipment (syringes, needles, alcohol pads), which are not included.
• Visuals: Vial appearance and cap color may vary from product photos; the label quantity refers to the total active content inside the vial.

Disclaimer: This product is sold explicitly as a chemical reagent for laboratory research and testing purposes only. It is not intended for human consumption, diagnostic, or therapeutic use. Bodily introduction of any kind into humans or animals is strictly forbidden by law.